Wednesday, September 20, 2023

Hillhurst Biopharmaceuticals Snags $3M SBIR

San Diego-based biopharmaceuticals company Hillhurst Biopharmaceuticals announced today that it has won $3M in a Phase 2b SBIR grant. According to the company, the award came from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. Hillhurst is developing liquid drug products with "therapeutic gases". The company said the funding will go towards a Phase 2a clinical study of HBI-002, an oral low dose carbon monoxide therapeutic candidate in patients with sickle cell disease (SCD).